摘要
目的:观察聚腺苷二磷酸核糖聚合酶(PARP)抑制剂奥拉帕利联合奈达铂腹腔热灌注化疗(HIPEC)治疗上皮性卵巢癌(EOC)的疗效。方法:选取EOC患者54例作为研究对象,采用随机数字表法随机分为对照组(27例,在常规治疗基础上加用奈达铂腹腔热灌注化疗)和观察组(27例,在对照组基础上联合奥拉帕利进行治疗)。比较两组患者治疗前后血清肿瘤标志物糖类抗原125(CA_(125))、血清人附睾蛋白4(HE4)水平、白细胞(WBC)计数、近期治疗效果、远期生存率以及不良反应发生情况。结果:治疗前两组患者CA_(125)、HE4水平及WBC计数比较差异无统计学意义(均P>0.05),治疗后观察组CA_(125)、HE4水平分别低于对照组(均P<0.05)。观察组患者近期有效率高于对照组(P<0.05)。两组患者1年生存率比较差异无统计学意义(P>0.05),观察组2年和3年生存率高于对照组(均P<0.05)。两组患者肾功能不全、骨髓抑制、听力异常、腹膜炎、脱发等不良反应发生情况比较,差异无统计学意义(均P>0.05)。结论:奥拉帕利联合奈达铂腹腔热灌注化疗能提高EOC患者近期疗效及远期生存率,且不良反应发生率无明显升高。
Objective:To observe the efficacy of polyadenosine diphosphate ribose polymerase(PARP)inhibitor olaparil combined with nedaplatin hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of epithelial ovarian cancer(EOC).Methods:54 EOC patients were selected and randomly divided into the control group(27 cases)and the observation group(27 cases).The control group received HIPEC with nedaplatin on the basis of conventional treatment.The observation group was treated with olaparib on the basis of the control group.The levels of carbohydrate antigen 125(CA_(125)),serum human epididymal protein 4(HE4)and white blood cell(WBC)count before and after treatment,and short-term treatment effect,long-term survival rate and occurrence of adverse reactions were compared between the two groups of patients.Results:There was no significant difference in the levels of CA_(125),HE4 and WBC count between the two groups before treatment(all P>0.05).After treatment,the levels of CA_(125) and HE4 in the observation group were lower than those in the control group(all P<0.05).The short-term effective rate in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).The 2-year and 3-year survival rates of the observation group were higher than those of the control group(all P<0.05).There was no statistically significant difference in the occurrence of adverse reactions such as renal insufficiency,bone marrow suppression,abnormal hearing,peritonitis,and alopecia between the two groups(all P>0.05).Conclusion:Olaparib combined with nedaplatin hyperthermic intraperitoneal chemotherapy can improve the short-term efficacy and long-term survival rate of EOC patients,and the incidence of adverse reactions does not increase significantly.
作者
张晶晶
岳丽娟
王莹
朱宏财
胡勇
ZHANG Jingjing;YUE Lijuan;WANG Ying;ZHU Hongcai;HU Yong(Department of Oncology,Hanzhong Central Hospital,Hanzhong 723000,China)
出处
《陕西医学杂志》
CAS
2021年第12期1566-1569,共4页
Shaanxi Medical Journal
基金
陕西省重点研发计划项目(2017SF-074)。
